Yes, LivaNova is publicly traded (NASDAQ: LIVN). It is a global medical technology company based in London, England, and Houston, Texas. The company became publicly traded in New York in June of 2016 when it merged with Sorin Group, a Milan-based medical device company.
LivaNova offers innovative medical technology and products that target the treatment of cardiovascular diseases, chronic pain and neurological disorders. Its products are sold in over 100 countries, and the company has operations and sales personnel in over 40 countries.
The company has presence in the United States, Europe, China and Japan. LivaNova is committed to providing innovative healthcare solutions and improved patient outcomes, and it focuses its efforts on developing and marketing state of the art product portfolios.
Table of Contents
How many employees does LivaNova have?
LivaNova is a global medical device company that specializes in the development, production and marketing of innovative medical technologies. As of 2020, LivaNova has approximately 5,500 employees across 56 countries.
The company has a presence in regions including North America, Europe, Asia, Latin America, the Middle East and Africa. LivaNova is driven by dedication to clinical excellence and innovation and it is focused on making a significant difference in the lives of people around the world.
When was LivaNova founded?
LivaNova was founded in 2015, formed through the merger of Sorin SpA and Cyberonics Inc. Both companies had deep foundations in their respective markets and Sorin SpA was founded in 1956 in Milan, Italy, while Cyberonics Inc.
was founded in 1987 in Houston, Texas. LivaNova has since become a global leader in medical technology, providing innovative technologies to treat patients with cardiac, neurological and other chronic conditions worldwide.
They focus on creating technological solutions that improve patient outcomes, reduce the complexity and costs of healthcare delivery, and build long-term partnerships with healthcare professionals and other organizations.
Who owns LivaNova?
LivaNova is a medical technology company that focuses on providing innovative solutions to improve patient outcomes. It was founded in 1976, and is headquartered in London, England. The company is owned jointly by Sorin Group S.
p. A, a leader in cardiac medical devices, and the private equity firm KKR. The two companies own a majority stake in LivaNova, and the rest is owned by Carnegie, a publicly-traded company based in the United Kingdom.
LivaNova provides products and therapies for various aspects of patient care, including cardiac, pulmonary, and neuromodulation. They also provide services such as clinical education and support, device manufacturing, and distribution.
The company has offices worldwide and has operations in the United States, Germany, Italy, France, United Kingdom, India, China, Japan, Brazil and Australia. LivaNova works to develop new therapies, improve existing ones, explore new technologies and advance patient care around the globe.
What industry is LivaNova?
LivaNova is a global medical technology company focused on delivering innovative product and service solutions to improve the lives of patients worldwide. They offer products to health care professionals in cardiology, vascular and diabetes arenas, as well as products to treat neurological disorders, brain trauma and advanced therapy products.
Their portfolio includes a diverse range of therapeutic solutions ranging from cardiovascular and metabolic, neurologic and anesthetic to minimally invasive surgery, bariatric and critical care products.
In 2020, the company had consolidated net revenue of approximately 1. 7 billion US dollars.
Who bought Cyberonics?
In April 2016, Cyberonics, Inc. was acquired by biopharmaceutical company Lundbeck A/S in a $2.3 billion deal.
The acquisition of Cyberonics, a Houston-based developer of Vagus Nerve Stimulation (VNS) technology, marks Lundbeck’s first venture into neurological therapy. Lundbeck’s decision to acquire Cyberonics was part of the company’s strategic plan to become a leader in brain diseases.
Lundbeck will also benefit from Cyberonics’ international presence, as well as its expertise in the stimulation of the vagus nerve.
Under the terms of the acquisition, all outstanding shares of Cyberonics, Inc. were acquired in exchange for an aggregate of $105 per share, representing the purchase of outstanding shares valued at $2.
3 billion. Cyberonics has more than 600 employees spread around the world, with its headquarters in Houston, Texas.
Following the acquisition, Cyberonics continues to be led by its current executive team and has joined Lundbeck’s existing Neurology business unit. In particular, Cyberonics’ expertise in stimulation of the vagus nerve will be a key asset to Lundbeck, which is primarily focused on developing psychiatry and neuroscience drugs.
In addition to the acquisition, Lundbeck and Cyberonics also entered into a research and collaboration agreement, which Lundbeck believes will expand its ability to provide innovative treatments for neurological and psychiatric disorders.
Through this alliance, Lundbeck will develop and gain access to new treatments, build its presence in neurological and psychiatric markets further, and enhance its position as a leader in brain diseases.
Is LivaNova a good company to work for?
Yes, LivaNova is a good company to work for. They are dedicated to providing quality products and services to their customers, operating in the health care, medical device and life sciences industries.
Their focus on innovation, technical expertise and high standards for quality, safety and efficacy helps ensure that their products and services meet the needs of their customers. Employees of LivaNova have access to competitive compensation and benefits packages, training and development opportunities, as well as a safe, inclusive and professional work environment.
LivaNova employees are also encouraged to have a sense of ownership in the company, being a part of something bigger and being given recognition for their achievements.
When was medical solutions founded?
Medical Solutions was founded in 2002 by Stacy McCallen, an experienced nurse and travel healthcare entrepreneur. The company started with the mission to help bridge the gap between healthcare providers and their travel assignments.
Since then, Medical Solutions has become one of the largest, most awarded, and fastest-growing travel healthcare staffing companies in the United States. The company works closely with healthcare facilities to provide the right people, the right skills, and the right solutions to meet their staffing needs.
Medical Solutions currently has a network of approximately 30,000 healthcare providers and offers solutions in nursing, allied health, locum tenens, and telemedicine. Medical Solutions is committed to creating opportunities that can benefit healthcare organizations and their travel healthcare professionals.
Did LivaNova buy Sorin?
Yes, in January 2016, medical device company LivaNova PLC acquired Sorin Group, a cardiac device maker and a portfolio company of private equity firm Montagu. The combined entity created one of the world’s leading medical device players, focused on the cardiac and vascular markets.
The combination of the two companies created LivaNova, a global medical technology company with operations in more than 100 countries. The company offers a broad portfolio of innovative products and technologies in the cardiac and vascular fields, including cardiac rhythm management, interventional cardiology and heart failure, structural heart disease and neurotechnology and neuromodulation.
The new company is expected to generate annual revenues of approximately $2. 3 billion, plus additional future revenue synergies. The deal is valued at €3 billion ($3. 35 billion), with LivaNova paying €2.
1 billion in cash and issuing 85. 7 million of its shares to complete the purchase.
The combination of Sorin and LivaNova is expected to strengthen the long-term growth of the two companies, providing diverse options for innovative product development, increased production capacity and a larger global reach.
Is LivaNova a buy?
It’s certainly a stock worth considering if you are looking for a buy. LivaNova is a leading global medical technology company with a broad portfolio of products across the healthcare continuum. It is well-known for its innovation in the medical device space.
LivaNova has an impressive track record of delivering strong financial performance, consistently beating Wall Street analyst’s consensus quarterly estimates. Currently, it has a strong balance sheet, bolstered by an increased focus on cost-cutting, and a diverse and profitable product portfolio.
The company’s core strength lies in its diversified product portfolio, which includes surgical systems, neuromodulation, cardiology, and patient monitoring systems. The company recently launched a new product offering, its SmartVena™ venous system, which is expected to drive future growth.
The stock has been outperforming the market so far this year, and is currently trading near its all-time high. Overall, with a focus on cost-cutting, efficient product development, and an expansive product portfolio, LivaNova could be a buy for long-term investors.
